Reprogramming of tumor-associated macrophages (TAMs) to a M1 macrophage via targeting TAMs or tumor cells by engineered M1-derived EVs decorating IL-4 receptor or CD47 via postinsertion of targeting peptide increased anti-tumor immunity (81, 82). This evidence concerns the gene CD47 and neoplasm.